Lead Product(s) : Rose Bengal Disodium
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : $3.0 million
Deal Type : Financing
Provectus Announces Seed Financing for VisiRose, Eye Drug Spinoff Company
Details : The financing is intended to support the clinical development of VisiRose’s formulated Rose Bengal Disodium for the treatment of infectious keratitis.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 14, 2025
Lead Product(s) : Rose Bengal Disodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : $3.0 million
Deal Type : Financing
Lead Product(s) : Rose Bengal Disodium,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : PV-10 (rose bengal sodium) Percutaneous intralesional injection, which is investigated in combination with standard of care immune checkpoint blockade (CB) for the treatment of Metastatic Uveal Melanoma.
Product Name : PV-10
Product Type : Small molecule
Upfront Cash : Not Applicable
November 13, 2023
Lead Product(s) : Rose Bengal Disodium,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable